One Little Baxalta(BXLT) Spark Of Corporate Gobbledygook

Baxalta(BXLT) completed its spinoff from Baxter International(BAX) yesterday. Or, as Baxalta would have it “Baxalta Launches as a Global Biopharmaceutical Leader Dedicated to Patients with Orphan Diseases and Underserved Conditions.”  Baxalta is no slouch, what with “New products and indications planned to contribute $2.5 billion in sales by 2020, building on base of $6 billion in annual revenue.”  The company’s management team is also “driving a patient-focused strategy.”

How will they accomplish all this? Simple! It’s the “Promise of the Baxalta Spark”. What is the Baxalta Spark? No, it’s not a new subcompact sedan. It’s everything good and sunshine.

Baxalta has embarked on a transformational journey to build an organization and culture where improving patients’ lives is at the center of the company strategy, values and behaviors.

“Baxalta has a renewed energy, as individuals and teams focus on accelerating innovation and access to our therapies while listening to and understanding our patients and the people who serve them on their journey,” said Hantson. “We are building a purpose-driven culture, one where employees and partners are empowered to contribute new ideas that will deliver strong performance for shareholders, breakthrough therapies and personalized services for patients, and meaningful and sustained value for all stakeholders.”

It’s purpose-driven! It’s patient-focused! There is renewed energy! With buzzwords like this, what could possibly go wrong?

Disclosure: The author holds no shares of any stock mentioned